MedTrace Logo

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

NCT00165308 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2014-07-09

No results posted yet for this study

Summary

The purpose of this study is determine whether or not tamoxifen reduces the chance of Hodgkin's Disease survivors developing breast cancer.

Conditions

Interventions

DRUG

Tamoxifen

Given orally, daily for one year.

Sponsors & Collaborators

Principal Investigators

  • Judy Garber, MD, MPH · Dana-Farber Cancer Institute

  • Lisa Diller, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Primary Completion
2004-03-31
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165308 on ClinicalTrials.gov